DRREDDY vs WINDLAS: Stock Comparison

Dr Reddys Laboratories Ltd vs Windlas Biotech Ltd

Live data: 27 July 2026, 4:08 PM IST • Source: NSE and company filings

Dr Reddys Laboratories Ltd is the larger company by market capitalisation. Dr Reddys Laboratories Ltd shows a higher net margin, while Windlas Biotech Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Dr Reddys Laboratories Ltd and Windlas Biotech Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, DRREDDY is more favourable on 4 of 13 scored metrics and WINDLAS on 9These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DRREDDY is the larger company
₹96,171 Cr vs ₹1,769 Cr
P/E Ratio
WINDLAS has a lower P/E
27.23x vs 29.85x
P/B Ratio
DRREDDY has a lower P/B
2.54x vs 3.12x
EPS
DRREDDY has higher earnings per share
₹39.73 vs ₹31.5
Dividend Yield
WINDLAS has a higher dividend yield
0.73% vs 0.69%
Revenue Growth (TTM YoY)
WINDLAS has faster revenue growth
17.7% vs -11.6%
EPS Growth (TTM YoY)
WINDLAS has faster EPS growth
-2.6% vs -86.2%
Qtr Sales Growth
WINDLAS has stronger quarterly sales growth
17.7% vs -11.5%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricDRREDDYWINDLAS
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricDRREDDYWINDLAS
Live Price₹1,150.8₹857.5
Day Change-0.08%-0.05%
Volume10.53 L23,569
52-Week High₹1,414.9₹1,097.9
52-Week Low₹1,101₹697.4
Distance from 52W High-18.67%-21.9%

Valuation

MetricDRREDDYWINDLAS
Market Cap₹96,171 Cr₹1,769 Cr
P/E Ratio29.85x27.23x
P/B Ratio2.54x3.12x
EPS₹39.73₹31.5
Book Value₹460.31₹275
Dividend Yield0.69%0.73%

Growth

MetricDRREDDYWINDLAS
Revenue Growth (TTM YoY)-11.6%17.7%
EPS Growth (TTM YoY)-86.2%-2.6%
Qtr Sales Growth-11.5%17.7%
Qtr Profit Growth-86.1%-1.78%

Profitability & Leverage

MetricDRREDDYWINDLAS
ROE11.2%12.2%
ROCE13%15.9%
Net Margin12.76%7.35%
Operating Margin19.2%11.6%
Debt to Equity0.2x0.06x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricDRREDDYWINDLAS
Promoter Holding26.64% 0.01 pp63.31% 1.41 pp
FII Holding32.07% 1.01 pp2.04% 1.44 pp
DII Holding31.74% 1.02 pp9.84% 1.97 pp
Public Holding9.35% 0.02 pp24.8% 0.9 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Dr Reddys Laboratories Ltd and Windlas Biotech Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.